A BILL 
To amend title XVIII of the Social Security Act to provide 
for the negotiation of lower covered part D drug prices 
on behalf of Medicare beneficiaries and the establishment 
and application of a formulary by the Secretary of 
Health and Human Services under Medicare part D, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
01:04 May 20, 2021
H2139
2 
•HR 2139 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Medicare Drug Price 
2
Negotiation Act’’. 
3
SEC. 2. NEGOTIATION OF LOWER COVERED PART D DRUG 
4
PRICES ON BEHALF OF MEDICARE BENE-
5
FICIARIES; ESTABLISHMENT AND APPLICA-
6
TION OF FORMULARY BY THE SECRETARY OF 
7
HEALTH 
AND 
HUMAN 
SERVICES 
UNDER 
8
MEDICARE PART D. 
9
(a) IN GENERAL.—Section 1860D–11 of the Social 
10
Security Act (42 U.S.C. 1395w–111) is amended by strik-
11
ing subsection (i) (relating to noninterference) and insert-
12
ing the following: 
13
‘‘(i) NEGOTIATION OF LOWER DRUG PRICES; ESTAB-
14
LISHMENT AND APPLICATION OF FORMULARY.— 
15
‘‘(1) NEGOTIATION.— 
16
‘‘(A) IN GENERAL.—Notwithstanding any 
17
other provision of law, subject to subparagraph 
18
(B), the Secretary shall, for plan years begin-
19
ning with plan year 2023— 
20
‘‘(i) negotiate with pharmaceutical 
21
manufacturers the prices (including dis-
22
counts, rebates, and all other price conces-
23
sions) that may be charged to PDP spon-
24
sors and MA organizations for covered 
25
part D drugs furnished to enrollees; and 
26
01:04 May 20, 2021
H2139
3 
•HR 2139 IH
‘‘(ii) complete such negotiations for a 
1
plan year not less than 30 days before the 
2
first day of the application review process 
3
for such plan year for new contracts or ex-
4
panding existing contracts with PDP spon-
5
sors and MA organizations to offer pre-
6
scription drug plans or MA–PD plans, re-
7
spectively. 
8
‘‘(B) USE OF FALLBACK IF NEGOTIATIONS 
9
FAIL.— 
10
‘‘(i) IN GENERAL.—If, after negotia-
11
tions under subparagraph (A), the Sec-
12
retary is not successful in obtaining a rea-
13
sonable price for covered part D drugs in 
14
accordance with clause (iii), the price that 
15
may be charged to PDP sponsors and MA 
16
organizations for such covered part D 
17
drugs furnished to enrollees shall be the 
18
lowest of the following: 
19
‘‘(I) The price applied pursuant 
20
to section 8126 of title 38, United 
21
States Code, for such drug for the 
22
year. 
23
‘‘(II) The median price available, 
24
during the most recent 12-month pe-
25
01:04 May 20, 2021
H2139
4 
•HR 2139 IH
riod for which data is available from 
1
the manufacturer to any wholesaler, 
2
retailer, provider, health maintenance 
3
organization, nonprofit entity, or gov-
4
ernmental entity in Canada, the 
5
United Kingdom, Germany, France, 
6
and Japan. 
7
‘‘(III) The average manufacturer 
8
price (as defined in subsection (k) of 
9
section 1927) for such drug for the 
10
most recent rebate period (as defined 
11
in such subsection) applicable to such 
12
plan year, reduced by the sum of the 
13
applicable rebate factors for the drug 
14
and rebate period. 
15
‘‘(ii) APPLICABLE REBATE FACTOR.— 
16
For purposes of clause (i)(III), the term 
17
‘applicable rebate factor’ means, with re-
18
spect to a covered part D drug and a re-
19
bate period (as defined in section 1927(k)), 
20
a dollar amount that applies for purposes 
21
of determining the amount of a rebate that 
22
is applicable to such drug for such rebate 
23
period under— 
24
01:04 May 20, 2021
H2139
5 
•HR 2139 IH
‘‘(I) paragraph (1)(A)(ii) of sec-
1
tion 1927(c); 
2
‘‘(II) paragraph (2)(A)(ii) of 
3
such section; 
4
‘‘(III) paragraph (2)(B) of such 
5
section; 
6
‘‘(IV) paragraph (2)(C) of such 
7
section; 
8
‘‘(V) paragraph (3)(A)(i) of such 
9
section; or 
10
‘‘(VI) paragraph (3)(C) of such 
11
section. 
12
‘‘(iii) GUIDANCE.—Not later than 60 
13
days after the date of enactment of this 
14
subsection, the Secretary shall issue guid-
15
ance on criteria to be considered for pur-
16
poses of determining under clause (i) 
17
whether or not the Secretary is successful 
18
in obtaining a reasonable price for a cov-
19
ered part D drug. Such criteria shall in-
20
clude at least the following: 
21
‘‘(I) The comparative clinical ef-
22
fectiveness and cost effectiveness, if 
23
available, of such covered part D 
24
drug. 
25
01:04 May 20, 2021
H2139
6 
•HR 2139 IH
‘‘(II) The budgetary impact of 
1
providing coverage under this part for 
2
such covered part D drug. 
3
‘‘(III) The number of similarly 
4
effective drug or alternative treatment 
5
regimens for each approved use of 
6
such covered part D drug. 
7
‘‘(IV) Associated unmet need or 
8
severity of illness. 
9
‘‘(C) IDENTIFICATION OF COVERED PART 
10
D DRUGS SUBJECT TO NEGOTIATION AND AP-
11
PLICATION OF NEGOTIATED PRICE.— 
12
‘‘(i) IDENTIFICATION.—The Secretary 
13
shall, for each plan year, in accordance 
14
with the subsequent clauses of this sub-
15
paragraph, and pursuant to rulemaking, 
16
identify covered part D drugs for which ne-
17
gotiations under subparagraph (A) shall be 
18
conducted. 
19
‘‘(ii) APPLICATION
OF
NEGOTIATED 
20
PRICE.—Except as provided in clause (iii), 
21
the negotiated price of a covered Part D 
22
drug shall be in effect for each subsequent 
23
plan year, and may be adjusted for infla-
24
tion, as measured by the percentage in-
25
01:04 May 20, 2021
H2139
7 
•HR 2139 IH
crease in the consumer price index for all 
1
urban consumers over the preceding year. 
2
‘‘(iii) 
PROCESS
FOR
RENEGOTI-
3
ATION.—The Secretary may establish a 
4
process whereby stakeholders may petition 
5
for the negotiated price of a covered Part 
6
D to be renegotiated after an appropriate 
7
length of time and only if evidence justi-
8
fying the need for such renegotiation is 
9
provided. 
10
‘‘(iv) REASONABLE
NOTIFICATION.— 
11
The Secretary shall carry out this subpara-
12
graph in such manner as to provide for 
13
public notification of the covered part D 
14
drugs subject to negotiations for a plan 
15
year within a reasonable period before the 
16
beginning of such negotiations. 
17
‘‘(D) PRIORITIZATION
OF
CERTAIN
COV-
18
ERED PART D DRUGS.—For purposes of sub-
19
paragraph (C)(i), the Secretary shall prioritize 
20
negotiating the prices of covered part D 
21
drugs— 
22
‘‘(i) that are among— 
23
‘‘(I) the 40 covered part D drugs 
24
that are utilized by at least 1,000 
25
01:04 May 20, 2021
H2139
8 
•HR 2139 IH
Medicare part D beneficiaries and 
1
with respect to which there were the 
2
highest total expenditures under this 
3
part during the most recent 12-month 
4
period for which data is available; 
5
‘‘(II) the 40 covered part D 
6
drugs that are utilized by at least 
7
1,000 Medicare part D beneficiaries 
8
with respect to whom the total annual 
9
spending per such a beneficiary under 
10
this part for coverage of such a drug 
11
is at least $10,000; or 
12
‘‘(III) the 20 covered part D 
13
drugs that are utilized by at least 
14
1,000 Medicare part D beneficiaries 
15
and with respect to which there are 
16
unit cost increases at or above the 
17
95th percentile of overall covered part 
18
D drug unit cost increases during the 
19
most recent 12-month period for 
20
which data is available; 
21
‘‘(ii) with respect to which the cost of 
22
such a drug to the part D eligible indi-
23
vidual involved would exceed the annual 
24
out-of-pocket threshold applicable under 
25
01:04 May 20, 2021
H2139
9 
•HR 2139 IH
section 1860D–2(b)(4)(B) for such plan 
1
year, if the drug were prescribed to the in-
2
dividual for the period of the year or with 
3
respect to which a single treatment regi-
4
men is priced above such annual out-of- 
5
pocket threshold applicable under such sec-
6
tion 1860D–2(b)(4)(B) for the year; or 
7
‘‘(iii) that are single-source drugs or 
8
biologicals 
(as 
defined 
in 
section 
9
1847A(c)(6)(D)) and that satisfy at least 
10
one other criterion described in a previous 
11
clause of this subparagraph. 
12
‘‘(E) ANNUAL
REPORT
TO
CONGRESS.— 
13
Not later than 30 days after the date on which 
14
the Secretary completes negotiations under this 
15
paragraph for the first plan year and each sub-
16
sequent plan year, the Secretary shall submit to 
17
Congress and make available to the public a re-
18
port describing the negotiations during the pre-
19
ceding year, including— 
20
‘‘(i) the number of covered part D 
21
drug prices negotiated; 
22
‘‘(ii) 
the 
magnitude 
of 
savings 
23
achieved as a result of such negotiations; 
24
01:04 May 20, 2021
H2139
10 
•HR 2139 IH
‘‘(iii) the number of times price nego-
1
tiations failed (based on the criteria in-
2
cluded in the guidance issued pursuant to 
3
clause (iii) of subparagraph (B)) and re-
4
sulted in the use of fallback prices under 
5
clause (i) of such subparagraph, and the 
6
rationale for any such decisions; 
7
‘‘(iv) the progress made toward nego-
8
tiating the prices of covered part D drugs 
9
that are prioritized under subparagraph 
10
(D); and 
11
‘‘(v) the barriers, if any, to achieving 
12
savings through negotiations. 
13
‘‘(F) EVALUATION.—Not later than De-
14
cember 31, 2026, the Inspector General of the 
15
Department of Health and Human Services 
16
shall submit to Congress a report evaluating the 
17
negotiations conducted by the Secretary under 
18
this paragraph, including a description and 
19
analysis of— 
20
‘‘(i) the extent to which such price ne-
21
gotiations are achieving lower prices for 
22
covered part D drugs for enrollees; 
23
‘‘(ii) the parties benefitting from such 
24
lower prices, such as enrollees, the Federal 
25
01:04 May 20, 2021
H2139
11 
•HR 2139 IH
Government, States, prescription drug 
1
plans and MA–PD plans, or other entities; 
2
‘‘(iii) how such price negotiations are 
3
affecting— 
4
‘‘(I) the list price of covered part 
5
D drugs; and 
6
‘‘(II) drug prices in the private 
7
market; and 
8
‘‘(iv) recommendations for improving 
9
price negotiations, if applicable. 
10
‘‘(2) ESTABLISHMENT
AND
APPLICATION
OF 
11
FORMULARY BY THE SECRETARY OR CHANGES IN 
12
FORMULARIES TO BE REQUIRED BY SECRETARY.— 
13
‘‘(A) IN GENERAL.—The Secretary shall, 
14
for plan years beginning with plan year 2023— 
15
‘‘(i) subject to subparagraphs (B) and 
16
(C), establish and apply a formulary for 
17
required use by sponsors of prescription 
18
drug plans and organizations offering MA– 
19
PD plans under this part; or 
20
‘‘(ii) require changes, as necessary, in 
21
the covered part D drugs included on 
22
formularies of PDP sponsors of prescrip-
23
tion drug plans (including changes, as nec-
24
essary, in the preferred or tiered cost-shar-
25
01:04 May 20, 2021
H2139
12 
•HR 2139 IH
ing status of such a drug) to take into ac-
1
count negotiations carried out by the Sec-
2
retary pursuant to paragraph (1), regard-
3
less of whether such a covered part D drug 
4
is the subject of such negotiations. 
5
‘‘(B) REQUIRED INCLUSION OF DRUGS IN 
6
ALL THERAPEUTIC CATEGORIES.—A formulary 
7
established and applied under subparagraph 
8
(A)(i) shall include at least two covered part D 
9
drugs in each category and class of covered part 
10
D 
drugs 
as 
described 
in 
section 
11
423.120(b)(2)(i) of title 42, Code of Federal 
12
Regulations (as in effect on January 1, 2019). 
13
‘‘(C) APPLICATION OF DEVELOPMENT AND 
14
REVISION REQUIREMENTS AND REQUIRED IN-
15
CLUSION
OF
ALL
DRUGS
IN
CERTAIN
CAT-
16
EGORIES AND CLASSES.—The requirements de-
17
scribed in subparagraphs (A) and (B) of section 
18
1860D–4(b)(3) (relating to development and re-
19
vision requirements of the formulary) and sub-
20
paragraph (G) of such section (relating to re-
21
quired inclusion of all drugs in certain cat-
22
egories and classes) shall apply to a formulary 
23
established and applied under subparagraph 
24
(A)(i) of this paragraph. 
25
01:04 May 20, 2021
H2139
13 
•HR 2139 IH
‘‘(3) PLAN FLEXIBILITY TO NEGOTIATE GREAT-
1
ER DISCOUNTS.—Nothing in this subsection shall be 
2
construed as preventing the sponsor of a prescrip-
3
tion drug plan, or an organization offering an MA– 
4
PD plan, from obtaining a discount or reduction of 
5
the price for a covered part D drug below the price 
6
negotiated under paragraph (1), if applicable, in-
7
cluding through the use of preferred or tiered cost- 
8
sharing status. 
9
‘‘(4) ENSURING
BENEFICIARY
ACCESS
TO 
10
NEEDED DRUGS.—Beginning with plan year 2023, 
11
each PDP sponsor of a prescription drug plan and 
12
organization offering an MA–PD plan shall have in 
13
place a process under which an enrollee in the plan 
14
may request coverage under the plan for a covered 
15
part D drug that is not on the formulary, or is sub-
16
ject to utilization management controls, such as 
17
tiered pricing, prior authorization, or step therapy.’’. 
18
(b) CONFORMING AMENDMENTS.— 
19
(1) IN GENERAL.—Section 1860D–4 of the So-
20
cial Security Act (42 U.S.C. 1395w–104) is amend-
21
ed— 
22
(A) in subsection (b)(3), in the matter pre-
23
ceding subparagraph (A), by striking ‘‘If a 
24
01:04 May 20, 2021
H2139
14 
•HR 2139 IH
PDP’’ and inserting ‘‘Subject to section 
1
1860D–11(i)(2), if a PDP’’; 
2
(B) in subsection (g)— 
3
(i) in paragraph (1), by inserting be-
4
fore the period at the end the following: ‘‘, 
5
except that the PDP sponsor of a prescrip-
6
tion drug plan shall treat the presentation 
7
of a prescription to a participating phar-
8
macy, which is transmitted to the plan by 
9
the pharmacy, as a request for a coverage 
10
determination (including with respect to 
11
prior authorization, step therapy, or quan-
12
tity limits) and, in applying such para-
13
graphs of section 1852(g), the response to 
14
such transmittal shall be treated as a de-
15
termination by the sponsor’’; and 
16
(ii) in paragraph (2), in the first sen-
17
tence, by inserting ‘‘(or a participating 
18
pharmacy, on behalf of such individual, 
19
through transmission of a prescription as 
20
described in paragraph (1))’’ after ‘‘a part 
21
D eligible individual who is enrolled in the 
22
plan’’; and 
23
(C) in subsection (h)— 
24
01:04 May 20, 2021
H2139
15 
•HR 2139 IH
(i) in paragraph (1), in the second 
1
sentence, by inserting ‘‘(or a participating 
2
pharmacy, on behalf of such individual)’’ 
3
after ‘‘the part D eligible individual’’; and 
4
(ii) in paragraph (2), by inserting 
5
‘‘(or a participating pharmacy, on behalf of 
6
such individual)’’ after ‘‘A part D eligible 
7
individual who is enrolled in a prescription 
8
drug plan offered by a PDP sponsor’’. 
9
(2) EFFECTIVE DATE.—The amendments made 
10
by subparagraphs (B) and (C) of paragraph (1) 
11
shall apply to plan years beginning on or after Janu-
12
ary 1, 2023. 
13
SEC. 3. REQUIRING DRUG MANUFACTURERS TO PROVIDE 
14
DRUG REBATES FOR DRUGS DISPENSED TO 
15
LOW-INCOME INDIVIDUALS. 
16
(a) IN GENERAL.—Section 1860D–2 of the Social 
17
Security Act (42 U.S.C. 1395w–102) is amended— 
18
(1) in subsection (e)(1), in the matter preceding 
19
subparagraph (A), by inserting ‘‘and subsection (f)’’ 
20
after ‘‘this subsection’’; and 
21
(2) by adding at the end the following new sub-
22
section: 
23
‘‘(f) PRESCRIPTION DRUG REBATE AGREEMENT FOR 
24
REBATE ELIGIBLE INDIVIDUALS.— 
25
01:04 May 20, 2021
H2139
16 
•HR 2139 IH
‘‘(1) REQUIREMENT.— 
1
‘‘(A) IN GENERAL.—For plan years begin-
2
ning on or after January 1, 2023, in this part, 
3
the term ‘covered part D drug’ does not include 
4
any drug or biological product that is manufac-
5
tured by a manufacturer that has not entered 
6
into and have in effect a rebate agreement de-
7
scribed in paragraph (2). 
8
‘‘(B) 2023 PLAN YEAR REQUIREMENT.— 
9
Any drug or biological product manufactured by 
10
a manufacturer that declines to enter into a re-
11
bate agreement described in paragraph (2) for 
12
the period beginning on January 1, 2023, and 
13
ending on December 31, 2023, shall not be in-
14
cluded as a ‘covered part D drug’ for the subse-
15
quent plan year. 
16
‘‘(2) REBATE
AGREEMENT.—A rebate agree-
17
ment under this subsection shall require the manu-
18
facturer to provide to the Secretary a rebate for 
19
each rebate period (as defined in paragraph (6)(B)) 
20
ending after December 31, 2022, in the amount 
21
specified in paragraph (3) for any covered part D 
22
drug of the manufacturer dispensed after December 
23
31, 2022, to any rebate eligible individual (as de-
24
fined in paragraph (6)(A)) for which payment was 
25
01:04 May 20, 2021
H2139
17 
•HR 2139 IH
made by a PDP sponsor or MA organization under 
1
this part for such period, including payments passed 
2
through the low-income and reinsurance subsidies 
3
under sections 1860D–14 and 1860D–15(b), respec-
4
tively. Such rebate shall be paid by the manufac-
5
turer to the Secretary not later than 30 days after 
6
the date of receipt of the information described in 
7
section 1860D–12(b)(8), including as such section is 
8
applied under section 1857(f)(3), or 30 days after 
9
the receipt of information under subparagraph (D) 
10
of paragraph (3), as determined by the Secretary. 
11
Insofar as not inconsistent with this subsection, the 
12
Secretary shall establish terms and conditions of 
13
such agreement relating to compliance, penalties, 
14
and program evaluations, investigations, and audits 
15
that are similar to the terms and conditions for re-
16
bate agreements under paragraphs (3) and (4) of 
17
section 1927(b). 
18
‘‘(3) REBATE FOR REBATE ELIGIBLE MEDICARE 
19
DRUG PLAN ENROLLEES.— 
20
‘‘(A) IN GENERAL.—The amount of the re-
21
bate specified under this paragraph for a manu-
22
facturer for a rebate period, with respect to 
23
each dosage form and strength of any covered 
24
part D drug provided by such manufacturer 
25
01:04 May 20, 2021
H2139
18 
•HR 2139 IH
and dispensed to a rebate eligible individual, 
1
shall be equal to the product of— 
2
‘‘(i) the total number of units of such 
3
dosage form and strength of the drug so 
4
provided and dispensed for which payment 
5
was made by a PDP sponsor or an MA or-
6
ganization under this part for the rebate 
7
period, including payments passed through 
8
the low-income and reinsurance subsidies 
9
under sections 1860D–14 and 1860D– 
10
15(b), respectively; and 
11
‘‘(ii) the amount (if any) by which— 
12
‘‘(I) the Medicaid rebate amount 
13
(as defined in subparagraph (B)) for 
14
such form, strength, and period, ex-
15
ceeds 
16
‘‘(II) the average Medicare drug 
17
program rebate eligible rebate amount 
18
(as defined in subparagraph (C)) for 
19
such form, strength, and period. 
20
‘‘(B) MEDICAID
REBATE
AMOUNT.—For 
21
purposes of this paragraph, the term ‘Medicaid 
22
rebate amount’ means, with respect to each 
23
dosage form and strength of a covered part D 
24
01:04 May 20, 2021
H2139
19 
•HR 2139 IH
drug provided by the manufacturer for a rebate 
1
period— 
2
‘‘(i) in the case of a single source 
3
drug or an innovator multiple source drug, 
4
the 
amount 
specified 
in 
paragraph 
5
(1)(A)(ii)(II) or (2)(C) of section 1927(c) 
6
plus the amount, if any, specified in sub-
7
paragraph (A)(ii) of paragraph (2) of such 
8
section, for such form, strength, and pe-
9
riod; or 
10
‘‘(ii) in the case of any other covered 
11
outpatient drug, the amount specified in 
12
paragraph (3)(A)(i) of such section for 
13
such form, strength, and period. 
14
‘‘(C) AVERAGE MEDICARE DRUG PROGRAM 
15
REBATE ELIGIBLE REBATE AMOUNT.—For pur-
16
poses of this subsection, the term ‘average 
17
Medicare drug program rebate eligible rebate 
18
amount’ means, with respect to each dosage 
19
form and strength of a covered part D drug 
20
provided by a manufacturer for a rebate period, 
21
the sum, for all PDP sponsors under part D 
22
and MA organizations administering an MA– 
23
PD plan under part C, of— 
24
01:04 May 20, 2021
H2139
20 
•HR 2139 IH
‘‘(i) the product, for each such spon-
1
sor or organization, of— 
2
‘‘(I) the sum of all rebates, dis-
3
counts, or other price concessions (not 
4
taking into account any rebate pro-
5
vided under paragraph (2) or any dis-
6
counts under the program under sec-
7
tion 1860D–14A) for such dosage 
8
form and strength of the drug dis-
9
pensed, calculated on a per-unit basis, 
10
but only to the extent that any such 
11
rebate, discount, or other price con-
12
cession applies equally to drugs dis-
13
pensed to rebate eligible Medicare 
14
drug plan enrollees and drugs dis-
15
pensed to PDP and MA–PD enrollees 
16
who are not rebate eligible individuals; 
17
and 
18
‘‘(II) the number of the units of 
19
such dosage and strength of the drug 
20
dispensed during the rebate period to 
21
rebate eligible individuals enrolled in 
22
the prescription drug plans adminis-
23
tered by the PDP sponsor or the MA– 
24
01:04 May 20, 2021
H2139
21 
•HR 2139 IH
PD plans administered by the MA or-
1
ganization; divided by 
2
‘‘(ii) the total number of units of such 
3
dosage and strength of the drug dispensed 
4
during the rebate period to rebate eligible 
5
individuals enrolled in all prescription drug 
6
plans administered by PDP sponsors and 
7
all MA–PD plans administered by MA or-
8
ganizations. 
9
‘‘(D) USE OF ESTIMATES.—The Secretary 
10
may establish a methodology for estimating the 
11
average Medicare drug program rebate eligible 
12
rebate amounts for each rebate period based on 
13
bid and utilization information under this part 
14
and may use these estimates as the basis for 
15
determining the rebates under this section. If 
16
the Secretary elects to estimate the average 
17
Medicare drug program rebate eligible rebate 
18
amounts, the Secretary shall establish a rec-
19
onciliation process for adjusting manufacturer 
20
rebate payments not later than 3 months after 
21
the date that manufacturers receive the infor-
22
mation 
collected 
under 
section 
1860D– 
23
12(b)(8)(B). 
24
01:04 May 20, 2021
H2139
22 
•HR 2139 IH
‘‘(4) LENGTH OF AGREEMENT.—The provisions 
1
of paragraph (4) of section 1927(b) (other than 
2
clauses (iv) and (v) of subparagraph (B)) shall apply 
3
to rebate agreements under this subsection in the 
4
same manner as such paragraph applies to a rebate 
5
agreement under such section. 
6
‘‘(5) OTHER
TERMS
AND
CONDITIONS.—The 
7
Secretary shall establish other terms and conditions 
8
of the rebate agreement under this subsection, in-
9
cluding terms and conditions related to compliance, 
10
that are consistent with this subsection. 
11
‘‘(6) DEFINITIONS.—In this subsection and sec-
12
tion 1860D–12(b)(8): 
13
‘‘(A) REBATE ELIGIBLE INDIVIDUAL.—The 
14
term ‘rebate eligible individual’ means— 
15
‘‘(i) a subsidy eligible individual (as 
16
defined in section 1860D–14(a)(3)(A)); 
17
‘‘(ii) a Medicaid beneficiary treated as 
18
a subsidy eligible individual under clause 
19
(v) of section 1860D–14(a)(3)(B); and 
20
‘‘(iii) any part D eligible individual 
21
not described in clause (i) or (ii) who is de-
22
termined for purposes of the State plan 
23
under title XIX to be eligible for medical 
24
01:04 May 20, 2021
H2139
23 
•HR 2139 IH
assistance under clause (i), (iii), or (iv) of 
1
section 1902(a)(10)(E). 
2
‘‘(B) REBATE PERIOD.—The term ‘rebate 
3
period’ has the meaning given such term in sec-
4
tion 1927(k)(8).’’. 
5
(b) REPORTING REQUIREMENT
FOR
THE DETER-
6
MINATION AND PAYMENT OF REBATES BY MANUFACTUR-
7
ERS RELATED TO REBATE FOR REBATE ELIGIBLE MEDI-
8
CARE DRUG PLAN ENROLLEES.— 
9
(1) REQUIREMENTS FOR PDP SPONSORS.—Sec-
10
tion 1860D–12(b) of the Social Security Act (42 
11
U.S.C. 1395w–112(b)) is amended by adding at the 
12
end the following new paragraph: 
13
‘‘(8) REPORTING REQUIREMENT FOR THE DE-
14
TERMINATION AND PAYMENT OF REBATES BY MANU-
15
FACTURERS RELATED TO REBATE FOR REBATE ELI-
16
GIBLE MEDICARE DRUG PLAN ENROLLEES.— 
17
‘‘(A) IN GENERAL.—For purposes of the 
18
rebate under section 1860D–2(f) for contract 
19
years beginning on or after January 1, 2023, 
20
each contract entered into with a PDP sponsor 
21
under this part with respect to a prescription 
22
drug plan shall require that the sponsor comply 
23
with subparagraphs (B) and (C). 
24
01:04 May 20, 2021
H2139
24 
•HR 2139 IH
‘‘(B) REPORT FORM AND CONTENTS.—Not 
1
later than a date specified by the Secretary, a 
2
PDP sponsor of a prescription drug plan under 
3
this part shall report to each manufacturer— 
4
‘‘(i) information (by National Drug 
5
Code number) on the total number of units 
6
of each dosage, form, and strength of each 
7
drug of such manufacturer dispensed to re-
8
bate eligible Medicare drug plan enrollees 
9
under any prescription drug plan operated 
10
by the PDP sponsor during the rebate pe-
11
riod; 
12
‘‘(ii) information on the price dis-
13
counts, price concessions, and rebates for 
14
such drugs for such form, strength, and 
15
period; 
16
‘‘(iii) information on the extent to 
17
which such price discounts, price conces-
18
sions, and rebates apply equally to rebate 
19
eligible Medicare drug plan enrollees and 
20
PDP enrollees who are not rebate eligible 
21
Medicare drug plan enrollees; and 
22
‘‘(iv) any additional information that 
23
the Secretary determines is necessary to 
24
enable the Secretary to calculate the aver-
25
01:04 May 20, 2021
H2139
25 
•HR 2139 IH
age Medicare drug program rebate eligible 
1
rebate amount (as defined in paragraph 
2
(3)(C) of such section), and to determine 
3
the amount of the rebate required under 
4
this section, for such form, strength, and 
5
period. 
6
Such report shall be in a form consistent with 
7
a standard reporting format established by the 
8
Secretary. 
9
‘‘(C) SUBMISSION TO SECRETARY.—Each 
10
PDP sponsor shall promptly transmit a copy of 
11
the information reported under subparagraph 
12
(B) to the Secretary for the purpose of audit 
13
oversight and evaluation. 
14
‘‘(D) 
CONFIDENTIALITY
OF
INFORMA-
15
TION.—The provisions of subparagraph (D) of 
16
section 1927(b)(3), relating to confidentiality of 
17
information, shall apply to information reported 
18
by PDP sponsors under this paragraph in the 
19
same manner that such provisions apply to in-
20
formation disclosed by manufacturers or whole-
21
salers under such section, except— 
22
‘‘(i) that any reference to ‘this sec-
23
tion’ in clause (i) of such subparagraph 
24
01:04 May 20, 2021
H2139
26 
•HR 2139 IH
shall be treated as being a reference to this 
1
section; 
2
‘‘(ii) the reference to the Director of 
3
the Congressional Budget Office in clause 
4
(iii) of such subparagraph shall be treated 
5
as including a reference to the Medicare 
6
Payment Advisory Commission; and 
7
‘‘(iii) clause (iv) of such subparagraph 
8
shall not apply. 
9
‘‘(E) OVERSIGHT.—Information reported 
10
under this paragraph may be used by the In-
11
spector General of the Department of Health 
12
and Human Services for the statutorily author-
13
ized purposes of audit, investigation, and eval-
14
uations. 
15
‘‘(F) PENALTIES
FOR
FAILURE
TO
PRO-
16
VIDE TIMELY INFORMATION AND PROVISION OF 
17
FALSE INFORMATION.—In the case of a PDP 
18
sponsor— 
19
‘‘(i) that fails to provide information 
20
required under subparagraph (B) on a 
21
timely basis, the sponsor is subject to a 
22
civil money penalty in the amount of 
23
$10,000 for each day in which such infor-
24
mation has not been provided; or 
25
01:04 May 20, 2021
H2139
27 
•HR 2139 IH
‘‘(ii) that knowingly (as defined in 
1
section 1128A(i)) provides false informa-
2
tion under such subparagraph, the sponsor 
3
is subject to a civil money penalty in an 
4
amount not to exceed $100,000 for each 
5
item of false information. 
6
Such civil money penalties are in addition to 
7
other penalties as may be prescribed by law. 
8
The provisions of section 1128A (other than 
9
subsections (a) and (b)) shall apply to a civil 
10
money penalty under this subparagraph in the 
11
same manner as such provisions apply to a pen-
12
alty or proceeding under section 1128A(a).’’. 
13
(2) APPLICATION TO MA ORGANIZATIONS.—Sec-
14
tion 1857(f)(3) of the Social Security Act (42 
15
U.S.C. 1395w–27(f)(3)) is amended by adding at 
16
the end the following: 
17
‘‘(E) REPORTING REQUIREMENT RELATED 
18
TO REBATE FOR REBATE ELIGIBLE MEDICARE 
19
DRUG
PLAN
ENROLLEES.—Section 1860D– 
20
12(b)(8).’’. 
21
(c) DEPOSIT OF REBATES INTO MEDICARE PRE-
22
SCRIPTION DRUG ACCOUNT.—Section 1860D–16(c) of the 
23
Social Security Act (42 U.S.C. 1395w–116(c)) is amended 
24
by adding at the end the following new paragraph: 
25
01:04 May 20, 2021
H2139
28 
•HR 2139 IH
‘‘(6) REBATE FOR REBATE ELIGIBLE MEDICARE 
1
DRUG PLAN ENROLLEES.—Amounts paid under a re-
2
bate agreement under section 1860D–2(f) shall be 
3
deposited into the Account.’’. 
4
(d) EXCLUSION FROM DETERMINATION
OF BEST 
5
PRICE
AND AVERAGE MANUFACTURER PRICE UNDER 
6
MEDICAID.— 
7
(1) EXCLUSION FROM BEST PRICE DETERMINA-
8
TION.—Section 1927(c)(1)(C)(ii)(I) of the Social Se-
9
curity Act (42 U.S.C. 1396r–8(c)(1)(C)(ii)(I)) is 
10
amended by inserting ‘‘and amounts paid under a 
11
rebate agreement under section 1860D–2(f)’’ after 
12
‘‘this section’’. 
13
(2) EXCLUSION
FROM
AVERAGE
MANUFAC-
14
TURER
PRICE
DETERMINATION.—Section 
15
1927(k)(1)(B)(i) of the Social Security Act (42 
16
U.S.C. 1396r–8(k)(1)(B)(i)) is amended— 
17
(A) in subclause (IV), by striking ‘‘and’’ 
18
after the semicolon; 
19
(B) in subclause (V), by striking the period 
20
at the end and inserting ‘‘; and’’; and 
21
(C) by adding at the end the following: 
22
01:04 May 20, 2021
H2139
29 
•HR 2139 IH
‘‘(VI) amounts paid under a re-
1
bate agreement under section 1860D– 
2
2(f).’’. 
3
Æ 
01:04 May 20, 2021
H2139
